{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:28:55Z","timestamp":1749554935896},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"PharmaEssentia Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02715-7","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T07:02:51Z","timestamp":1701068571000},"page":"847-856","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct05808322","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wang-Da","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko-Jen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Yen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"6937","key":"2715_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/423240a","volume":"423","author":"RA Fouchier","year":"2003","unstructured":"Fouchier RA, Kuiken T, Schutten M, et al. Koch\u2019s postulates fulfilled for SARS virus. Nature. 2003;423(6937):240.","journal-title":"Nature"},{"issue":"8","key":"2715_CR2","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.3390\/v2081803","volume":"2","author":"PCY Woo","year":"2010","unstructured":"Woo PCY, Huang Y, Lau SKP, Yuen KY. Coronavirus genomics and bioinformatics analysis. Viruses. 2010;2(8):1804\u201320.","journal-title":"Viruses"},{"issue":"3","key":"2715_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181\u201392.","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2715_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141\u201354.","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"2715_CR5","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/jmv.27588","volume":"94","author":"Y Araf","year":"2022","unstructured":"Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825\u201332.","journal-title":"J Med Virol"},{"key":"2715_CR6","unstructured":"National Institutes of Health. COVID-19 treatment guidelines. Last updated March 6, 2023. https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/."},{"key":"2715_CR7","doi-asserted-by":"crossref","unstructured":"Hogan JI, Duerr R, Dimartino D, et al. Remdesivir resistance in transplant recipients with persistent COVID-19. Res Sq. 2022;rs.3.rs-1800050.","DOI":"10.21203\/rs.3.rs-1800050\/v1"},{"issue":"3","key":"2715_CR8","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1093\/cid\/ciac496","volume":"76","author":"AF Carlin","year":"2023","unstructured":"Carlin AF, Clark AE, Chaillon A, et al. Virologic and immunologic characterization of coronavirus disease 2019 recrudescence after nirmatrelvir\/ritonavir treatment. Clin Infect Dis. 2023;76(3):e530\u20132.","journal-title":"Clin Infect Dis"},{"key":"2715_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.855496","volume":"13","author":"L Tian","year":"2022","unstructured":"Tian L, Pang Z, Li M, et al. Molnupiravir and its antiviral activity against COVID-19. Front Immunol. 2022;13:855496.","journal-title":"Front Immunol"},{"issue":"7898","key":"2715_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657\u201363.","journal-title":"Nature"},{"issue":"3","key":"2715_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/annrheumdis-2020-218946","volume":"80","author":"S Akiyama","year":"2021","unstructured":"Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2715_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.20892\/j.issn.2095-3941.2020.0559","volume":"18","author":"L Yang","year":"2021","unstructured":"Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1):298\u2013307.","journal-title":"Cancer Biol Med"},{"key":"2715_CR13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.2147\/RMHP.S292538","volume":"14","author":"YS Jang","year":"2021","unstructured":"Jang YS, Seon JY, Yoon SJ, Park SY, Lee SH, Oh IH. Comorbidities and factors determining medical expenses and length of stay for admitted COVID-19 patients in Korea. Risk Manag Healthc Policy. 2021;14:2021\u201333.","journal-title":"Risk Manag Healthc Policy"},{"key":"2715_CR14","doi-asserted-by":"publisher","first-page":"2349890","DOI":"10.1155\/2022\/2349890","volume":"2022","author":"R Koyyada","year":"2022","unstructured":"Koyyada R, Nagalla B, Tummala A, et al. Prevalence and impact of preexisting comorbidities on overall clinical outcomes of hospitalized COVID-19 patients. Biomed Res Int. 2022;2022:2349890.","journal-title":"Biomed Res Int"},{"issue":"26","key":"2715_CR15","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.2217\/fon-2021-0121","volume":"17","author":"M Aboueshia","year":"2021","unstructured":"Aboueshia M, Hussein MH, Attia AS, et al. Cancer and COVID-19: analysis of patient outcomes. Future Oncol. 2021;17(26):3499\u2013510.","journal-title":"Future Oncol"},{"issue":"5","key":"2715_CR16","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.dsx.2020.07.037","volume":"14","author":"AA Salunke","year":"2020","unstructured":"Salunke AA, Nandy K, Pathak SK, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5):1431\u20137.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"2715_CR17","doi-asserted-by":"publisher","first-page":"pkaa102","DOI":"10.1093\/jncics\/pkaa102","volume":"5","author":"BP Venkatesulu","year":"2021","unstructured":"Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021;5(2):pkaa102.","journal-title":"JNCI Cancer Spectr"},{"key":"2715_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100091","volume":"4","author":"JM Anaya","year":"2021","unstructured":"Anaya JM, Monsalve DM, Rojas M, et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun. 2021;4:100091.","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"2715_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/QCO.0000000000000841","volume":"35","author":"JC Laracy","year":"2022","unstructured":"Laracy JC, Kamboj M, Vardhana SA. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr Opin Infect Dis. 2022;35(4):271\u20139.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"2715_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","volume":"12","author":"CY Lee","year":"2022","unstructured":"Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12(1):62\u201373.","journal-title":"Cancer Discov"},{"issue":"1","key":"2715_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/cimb45010003","volume":"45","author":"JV Garmendia","year":"2022","unstructured":"Garmendia JV, Garc\u00eda AH, De Sanctis CV, Hajd\u00fach M, De Sanctis JB. Autoimmunity and immunodeficiency in severe SARS-CoV-2 infection and prolonged COVID-19. Curr Issues Mol Biol. 2022;45(1):33\u201350.","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"2715_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S1473-3099(21)00464-3","volume":"21","author":"E Moran","year":"2021","unstructured":"Moran E, Cook T, Goodman AL, et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect Dis. 2021;21(10):1345\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"2715_CR23","doi-asserted-by":"publisher","first-page":"jiaa446","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup K, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):jiaa446.","journal-title":"J Infect Dis"},{"issue":"2","key":"2715_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab F, Mayer-Barber K, Sher A, Wack A, O\u2019Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87\u2013103.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2715_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2008","unstructured":"Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008;8(7):559\u201368.","journal-title":"Nat Rev Immunol"},{"key":"2715_CR26","doi-asserted-by":"publisher","first-page":"1173467","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol. 2023;13:1173467.","journal-title":"Front Oncol"},{"key":"2715_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648004","volume":"12","author":"M Contoli","year":"2021","unstructured":"Contoli M, Papi A, Tomassetti L, et al. Blood interferon-\u03b1 levels and severity, outcomes, and inflammatory profiles in hospitalized COVID-19 patients. Front Immunol. 2021;12:648004.","journal-title":"Front Immunol"},{"issue":"6504","key":"2715_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718\u201324.","journal-title":"Science"},{"issue":"6515","key":"2715_CR29","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","volume":"370","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.","journal-title":"Science"},{"issue":"6515","key":"2715_CR30","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585.","journal-title":"Science"},{"issue":"7","key":"2715_CR31","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1086\/382597","volume":"189","author":"U Str\u00f6her","year":"2004","unstructured":"Str\u00f6her U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis. 2004;189(7):1164\u20137.","journal-title":"J Infect Dis"},{"issue":"10","key":"2715_CR32","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2174\/1568026621666210429083050","volume":"21","author":"Z Meng","year":"2021","unstructured":"Meng Z, Wang T, Chen L, et al. The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area. Curr Top Med Chem. 2021;21(10):920\u20137.","journal-title":"Curr Top Med Chem"},{"key":"2715_CR33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, et al. Interferon-a2b treatment for COVID-19. Front Immunol. 2020;11:1061.","journal-title":"Front Immunol"},{"key":"2715_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ijid.2021.08.044","volume":"111","author":"BLS Bhushan","year":"2021","unstructured":"Bhushan BLS, Wanve S, Koradia P, et al. Efficacy and safety of pegylated interferon-\u03b12b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. Int J Infect Dis. 2021;111:281\u20137.","journal-title":"Int J Infect Dis"},{"key":"2715_CR35","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","volume":"105","author":"A Pandit","year":"2021","unstructured":"Pandit A, Bhalani N, Bhushan BLS, et al. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: a phase II, randomized, controlled, open-label study. Int J Infect Dis. 2021;105:516\u201321.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"2715_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12325-021-01998-y","volume":"39","author":"KY Chen","year":"2022","unstructured":"Chen KY, Lee KY, Qin A, et al. Clinical experience with ropeginterferon alfa-2b in the off-label use for the treatment of COVID-19 patients in Taiwan. Adv Ther. 2022;39(2):910\u201322.","journal-title":"Adv Ther"},{"key":"2715_CR37","unstructured":"Feng PH, Liu WD, Cheng CY, et al. Ropeginterferon alfa-2b therapy for moderate to severe COVID-19: a phase 3, randomized controlled clinical trial. J Microbiol Immunol Infect. 2023 (under review)."},{"key":"2715_CR38","unstructured":"US Food and Drug Administration. FDA approves treatment for rare blood disease: treatment is first FDA-approved option patients can take regardless of previous therapies. Nov 12, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease#:~:text=Rare%20Blood%20Disease-,FDA%20NEWS%20RELEASE,-FDA%20Approves%20Treatment. Accessed Jul 18, 2023."},{"key":"2715_CR39","unstructured":"European Medicines Agency. Besremi: EPAR-medicine overview. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/besremi. Accessed Jul 18, 2023."},{"issue":"11","key":"2715_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2217\/fon-2022-1141","volume":"19","author":"J Jin","year":"2023","unstructured":"Jin J, Qin A, Zhang L, et al. A phase II trial to assess the efficacy and safety of ropeginterferon \u03b1-2b in Chinese patients with polycythemia vera. Future Oncol. 2023;19(11):753\u201361.","journal-title":"Future Oncol"},{"issue":"1","key":"2715_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023;12(1):55.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2715_CR42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","volume":"120","author":"CE Huang","year":"2021","unstructured":"Huang CE, Wu YY, Hsu CC, et al. Real-world experience with ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc. 2021;120(2):863\u201373.","journal-title":"J Formos Med Assoc"},{"issue":"27","key":"2715_CR43","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2217\/fon-2022-0596","volume":"18","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Komatsu N, Gill H, et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022;18(27):2999\u20133009.","journal-title":"Future Oncol"},{"key":"2715_CR44","doi-asserted-by":"publisher","first-page":"1109866","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbansky RW, Yu L, Ahmed T, Mascrenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866.","journal-title":"Front Oncol"},{"issue":"6","key":"2715_CR45","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","volume":"14","author":"YW Huang","year":"2020","unstructured":"Huang YW, Hsu CW, Lu SN, et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol Int. 2020;14(6):997\u20131008.","journal-title":"Hepatol Int"},{"issue":"8","key":"2715_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jgh3.12613","volume":"5","author":"HH Lin","year":"2021","unstructured":"Lin HH, Hsu SJ, Lu SN, et al. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: pharmacokinetics, safety, and preliminary efficacy. JGH Open. 2021;5(8):929\u201340.","journal-title":"JGH Open"},{"issue":"3","key":"2715_CR47","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","volume":"120","author":"SJ Hsu","year":"2021","unstructured":"Hsu SJ, Yu ML, Su CW, et al. Ropeginterferon alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J Formos Med Assoc. 2021;120(3):956\u201364.","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"2715_CR48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/jgh3.12825","volume":"6","author":"CY Chen","year":"2022","unstructured":"Chen CY, Chuang WL, Qin A, et al. A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. JGH Open. 2022;6(11):782\u201391.","journal-title":"JGH Open"},{"issue":"6","key":"2715_CR49","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/v14061128","volume":"14","author":"YW Huang","year":"2022","unstructured":"Huang YW, Qin A, Tsai CY, Chen PJ. Novel pegylated interferon for the treatment of chronic viral hepatitis. Viruses. 2022;14(6):1128.","journal-title":"Viruses"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02715-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02715-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02715-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T07:22:15Z","timestamp":1707031335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02715-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2715"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02715-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wang-Huei Sheng, Wang-Da Liu, and Ko-Jen Li declare no conflict of interest. Hsin-An Hou declares the honorarium, travel and research support from PharmaEssentia Corporation. Albert Qin and Chan-Yen Tsai work for PharmaEssentia Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study is approved by the institutional review board of NTUH IRB (approval number 202302136MIPD) and follows the principles of the Declaration of Helsinki for all human experimental investigations. Informed consent will be obtained from all participating patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}